AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32271718 — intervention group
Group type: EXPERIMENTAL
Intervention: Exebacase + antibiotics (MRSA patients)
Number of subjects: 121
Study 32271718 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone (MRSA patients)
Number of subjects: 121
Study 33993501 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks until week 52
Number of subjects: 438
Study 33993501 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks until week 24, then 300 mg every 4 weeks until week 52
Number of subjects: 438
Study 33993501 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mometasone furoate nasal spray) until week 52
Number of subjects: 438
Study 32682815 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 94
Study 32682815 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 94
Study 35896277 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor-based therapy (a fixed combination of perindopril and indapamide)
Number of subjects: 9694
Study 35896277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9694
Study 35896277 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor-based therapy
Number of subjects: 9694
Study 33823423 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music intervention with rhythmic exercises program
Number of subjects: 40
Study 33823423 — intervention group
Group type: COMPARATOR
Intervention: Regular activities program
Number of subjects: 40
Study 36351735 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief pain consult (BPC) followed by telehealth physical therapy (PT) in the first 12 weeks (sequenced delivery strategy)
Number of subjects: 500
Study 36351735 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief pain consult (BPC) followed by telehealth physical therapy (PT) for non-responders (adaptive strategy)
Number of subjects: 500
Study 33233955 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group (submaximal aerobic exercise + drug therapy)
Number of subjects: 0
Study 33233955 — intervention group
Group type: COMPARATOR
Intervention: Single drug group (drug therapy only)
Number of subjects: 0
Study 33174234 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing (SRP) with adjunctive glycine powder air-polishing (GPAP)
Number of subjects: 41
Study 33174234 — intervention group
Group type: COMPARATOR
Intervention: Full-mouth scaling and root planing (SRP)
Number of subjects: 41
Study 32438407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD)
Number of subjects: 6294
Study 32438407 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuated CTD (CTDa)
Number of subjects: 6294
Study 32438407 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, lenalidomide, and dexamethasone (CRD)
Number of subjects: 6294
Study 32438407 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuated CRD (CRDa)
Number of subjects: 6294
Study 32438407 — intervention group
Group type: COMPARATOR
Intervention: Thromboprophylaxis
Number of subjects: 6294
Study 34823018 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1,000 mg twice daily)
Number of subjects: 415
Study 34823018 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin
Number of subjects: 415
Study 34823018 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-bolus insulin
Number of subjects: 415
Study 34823018 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin
Number of subjects: 415
Study 32063231 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion recognition training (CBM)
Number of subjects: 190
Study 32063231 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 190
Study 36442533 — intervention group
Group type: EXPERIMENTAL
Intervention: Presurgical regional anesthesia block
Number of subjects: 98
Study 36442533 — intervention group
Group type: COMPARATOR
Intervention: Control group (no regional anesthesia block)
Number of subjects: 98
Study 33535025 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated model of care for community-dwelling older people
Number of subjects: 0
Study 32420649 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (15 mg daily)
Number of subjects: 60
Study 32420649 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (75 mg daily)
Number of subjects: 60
Study 35148753 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed PMDD
Number of subjects: 110
Study 35148753 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous psychological treatment for PMDD
Number of subjects: 110
Study 35148753 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher depressive symptoms in the late luteal phase
Number of subjects: 110
Study 35148753 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher self-rated health
Number of subjects: 110
Study 34223077 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (2 g, oral dose)
Number of subjects: 829
Study 32551796 — intervention group
Group type: EXPERIMENTAL
Intervention: Ninjin'yoeito (NYT)
Number of subjects: 62
Study 32551796 — intervention group
Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 62
Study 33492394 — intervention group
Group type: EXPERIMENTAL
Intervention: Low salt diet (LSD, 3 g NaCl/day)
Number of subjects: 16
Study 33492394 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal salt diet (NSD, 6 g NaCl/day)
Number of subjects: 16
Study 33492394 — intervention group
Group type: EXPERIMENTAL
Intervention: High salt diet (HSD, 15 g NaCl/day)
Number of subjects: 16
Study 34908567 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg (Group A)
Number of subjects: 100
Study 34908567 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol 50 mg (Group B)
Number of subjects: 100
Study 36397446 — intervention group
Group type: EXPERIMENTAL
Intervention: LJR ointment
Number of subjects: 46
Study 36397446 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 46
Study 32622918 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal ice pack applied directly on the lower abdomen for 12 hours postoperation, with continued use encouraged for up to 48 hours after discharge.
Number of subjects: 142
Study 32622918 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ice pack).
Number of subjects: 142
Study 32622918 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal ice pack use satisfaction.
Number of subjects: 142
Study 36450745 — intervention group
Group type: EXPERIMENTAL
Intervention: hADM
Number of subjects: 20
Study 36450745 — intervention group
Group type: COMPARATOR
Intervention: PP mesh
Number of subjects: 20
Study 33231881 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated Specialty Care (CSC) intervention called NAVIGATE
Number of subjects: 0
Study 33231881 — intervention group
Group type: COMPARATOR
Intervention: Usual community care
Number of subjects: 0
Study 32650347 — intervention group
Group type: EXPERIMENTAL
Intervention: APC with power set at 90W and 120mg omeprazole
Number of subjects: 71
Study 32650347 — intervention group
Group type: EXPERIMENTAL
Intervention: APC with power set at 90W and 40mg omeprazole
Number of subjects: 71
Study 32650347 — intervention group
Group type: EXPERIMENTAL
Intervention: APC with power set at 60W and 120mg omeprazole
Number of subjects: 71
Study 32650347 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adverse events
Number of subjects: 71
Study 32650347 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest pain/discomfort
Number of subjects: 71
Study 32650347 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 71
Study 32573795 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant 100 mg
Number of subjects: 1938
Study 32573795 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant 100 mg plus Sumatriptan 100 mg
Number of subjects: 1938
Study 32573795 — intervention group
Group type: COMPARATOR
Intervention: Ubrogepant 100 mg with Triptan as rescue medication
Number of subjects: 1938
Study 32573795 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan 100 mg
Number of subjects: 1938
Study 35101070 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-generate physiological coherence system (SPCS) focus training for 12 weeks
Number of subjects: 0
Study 32193413 — intervention group
Group type: EXPERIMENTAL
Intervention: In-line filtration
Number of subjects: 146
Study 32193413 — intervention group
Group type: COMPARATOR
Intervention: Standard care without filters
Number of subjects: 146
Study 32738069 — intervention group
Group type: EXPERIMENTAL
Intervention: Long array (31.5 mm)
Number of subjects: 2
Study 32738069 — intervention group
Group type: COMPARATOR
Intervention: Short array (24 mm)
Number of subjects: 2
Study 34074993 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 22
Study 34074993 — intervention group
Group type: COMPARATOR
Intervention: SMILE
Number of subjects: 22
Study 33087441 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Channel Blockers (CCBs)
Number of subjects: 52
Study 33087441 — intervention group
Group type: COMPARATOR
Intervention: Beta Blockers (BBs)
Number of subjects: 52
Study 33087441 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BBs and CCBs)
Number of subjects: 52
Study 35382966 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg/day)
Number of subjects: 16
Study 35382966 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 16
Study 33187752 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tramadol
Number of subjects: 54
Study 33187752 — intervention group
Group type: COMPARATOR
Intervention: Verbal analgesia
Number of subjects: 54
Study 36123649 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Treatment with Peer Support (HT + PS)
Number of subjects: 286
Study 36123649 — intervention group
Group type: COMPARATOR
Intervention: Home Treatment (HT)
Number of subjects: 286
Study 32181756 — intervention group
Group type: EXPERIMENTAL
Intervention: HD‐MAPs delivering 15 μg HA
Number of subjects: 60
Study 32181756 — intervention group
Group type: EXPERIMENTAL
Intervention: HD‐MAPs delivering 10 μg HA
Number of subjects: 60
Study 32181756 — intervention group
Group type: COMPARATOR
Intervention: IM injection of QIV (15 μg/dose)
Number of subjects: 60
Study 34146029 — intervention group
Group type: EXPERIMENTAL
Intervention: Stromal wound hydration
Number of subjects: 320
Study 34146029 — intervention group
Group type: COMPARATOR
Intervention: No stromal wound hydration
Number of subjects: 320
Study 32268306 — intervention group
Group type: EXPERIMENTAL
Intervention: Rule-based real-time PB detection system
Number of subjects: 0
Study 35624519 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-compassion training (practising mindfulness, writing a letter to themselves offering support)
Number of subjects: 18
Study 35624519 — intervention group
Group type: COMPARATOR
Intervention: Behaviour change education (SMART goals, action-coping planning)
Number of subjects: 18
Study 33452219 — intervention group
Group type: EXPERIMENTAL
Intervention: MedinCNO
Number of subjects: 20
Study 33452219 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Flow (IF)
Number of subjects: 20
Study 33452219 — intervention group
Group type: EXPERIMENTAL
Intervention: Servo‐i
Number of subjects: 20
Study 34459002 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 724
Study 34459002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 724
Study 32374844 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA-dependent variants (via AGO2 and miR-17 binding)
Number of subjects: 0
Study 32374844 — intervention group
Group type: EXPERIMENTAL
Intervention: let-7 binding
Number of subjects: 0
Study 32374844 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA-independent variants (acquired through compensatory mutations)
Number of subjects: 0
Study 32374844 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA binding and 3' mutagenesis
Number of subjects: 0
Study 36203410 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-diameter implants (NDI) Ø3.5 mm
Number of subjects: 50
Study 36203410 — intervention group
Group type: COMPARATOR
Intervention: Standard-diameter implants (SDI) Ø4.3 mm with lateral bone augmentation
Number of subjects: 50
Study 33630870 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide M49 conjugated with monomethyl auristatin E (PDC)
Number of subjects: 0
Study 33630870 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide M49
Number of subjects: 0
Study 33630870 — intervention group
Group type: EXPERIMENTAL
Intervention: HLH peptides and their PDCs
Number of subjects: 0
Study 32385943 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite (3.0 mL)
Number of subjects: 20
Study 32385943 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite plus HIFU (400 lines after 4 weeks)
Number of subjects: 20
Study 32385943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 36043711 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALCAR) 1.5 g BID for 3 months
Number of subjects: 92
Study 32917151 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstetric early warning system (EWS) model based on clinical observations including systolic blood pressure, diastolic blood pressure, respiratory rate, temperature, pulse rate, caesarean-birth, and previous caesarean-births.
Number of subjects: 1500
Study 32917151 — intervention group
Group type: EXPERIMENTAL
Intervention: Low urine output (300mls/24 h) and prolonged unconsciousness (GCS < 8/15) as predictors of SMO in univariate analysis.
Number of subjects: 1500
Study 32917151 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation dataset performance of the EWS model.
Number of subjects: 1500
Study 35170216 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice-daily plus aspirin
Number of subjects: 6564
Study 35170216 — intervention group
Group type: COMPARATOR
Intervention: Placebo on aspirin background
Number of subjects: 6564
Study 34052087 — intervention group
Group type: EXPERIMENTAL
Intervention: Open cell polyurethane foam cushions
Number of subjects: 22
Study 34052087 — intervention group
Group type: EXPERIMENTAL
Intervention: Horseshoe cushion (open cell polyurethane foam)
Number of subjects: 22
Study 34052087 — intervention group
Group type: COMPARATOR
Intervention: Injected polyurethane foam and gel cushions
Number of subjects: 22
Study 35219973 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy combined with trunk restraint
Number of subjects: 36
Study 35219973 — intervention group
Group type: COMPARATOR
Intervention: Robot-assisted therapy
Number of subjects: 36
Study 33963832 — intervention group
Group type: EXPERIMENTAL
Intervention: StackIL6 model
Number of subjects: 0
Study 33963832 — intervention group
Group type: COMPARATOR
Intervention: IL6PRED (existing method)
Number of subjects: 0
Study 32807158 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at a single acupoint
Number of subjects: 0
Study 32807158 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of multi-acupoints
Number of subjects: 0
Study 32807158 — intervention group
Group type: COMPARATOR
Intervention: Sham point
Number of subjects: 0
Study 32807158 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography
Number of subjects: 0
Study 32807158 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting state functional MRI (rs-fMRI)
Number of subjects: 0
Study 36078945 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous training (50–60% VO2peak, 30–45 min, 3 d/week)
Number of subjects: 33
Study 36078945 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval training (90% VO2peak, 1–4 min, 3 d/week)
Number of subjects: 33
Study 36078945 — intervention group
Group type: COMPARATOR
Intervention: Sham exercise placebo
Number of subjects: 33
Study 33401489 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated depression treatment and economic strengthening intervention
Number of subjects: 48
Study 33401489 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 48
Study 32996347 — intervention group
Group type: EXPERIMENTAL
Intervention: CLS-FUERTE (multicomponent behavioral Evidence-Based Treatment)
Number of subjects: 58
Study 32996347 — intervention group
Group type: COMPARATOR
Intervention: Usual school services
Number of subjects: 58
Study 32558907 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of genomic-SSR markers in Zanthoxylum bungeanum
Number of subjects: 15
Study 32558907 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis using SSR markers
Number of subjects: 15
Study 36378318 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision aid (DA) in addition to usual care (UC)
Number of subjects: 96
Study 36378318 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 96
Study 33608568 — intervention group
Group type: EXPERIMENTAL
Intervention: noisy galvanic vestibular stimulation (nGVS)
Number of subjects: 10
Study 32941649 — intervention group
Group type: EXPERIMENTAL
Intervention: HDT/ASCT
Number of subjects: 431
Study 35887739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional Rounding
Number of subjects: 1822
Study 35887739 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care
Number of subjects: 1822
Study 33530205 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and Muscle Relaxation (EMR) program
Number of subjects: 110
Study 33530205 — intervention group
Group type: COMPARATOR
Intervention: Control group (common rehabilitation advice)
Number of subjects: 110
Study 34389292 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin per day, initiated from 12 to 20 gestational weeks until 34 weeks of gestation.
Number of subjects: 898
Study 34389292 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aspirin).
Number of subjects: 898
Study 34389292 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin per day.
Number of subjects: 898
Study 33985457 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical glove compression therapy (two one-size-smaller gloves on one hand)
Number of subjects: 56
Study 33985457 — intervention group
Group type: COMPARATOR
Intervention: Control (two normal-size gloves on the other hand)
Number of subjects: 56
Study 34426568 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 1.5 mg/kg + dexmedetomidine 4 μg/kg (HND group)
Number of subjects: 219
Study 34426568 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 1.0 mg/kg + dexmedetomidine 4 μg/kg (MND group)
Number of subjects: 219
Study 34426568 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 0.5 mg/kg + dexmedetomidine 4 μg/kg (LND group)
Number of subjects: 219
Study 34426568 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil 2.5 μg/kg (Control group)
Number of subjects: 219
Study 32032404 — intervention group
Group type: EXPERIMENTAL
Intervention: MCAT+SCTG+rhPDGF-BB
Number of subjects: 24
Study 32032404 — intervention group
Group type: COMPARATOR
Intervention: MCAT+SCTG
Number of subjects: 24
Study 36050514 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine in SARDs patients
Number of subjects: 142
Study 36050514 — intervention group
Group type: COMPARATOR
Intervention: BNT162b2 vaccine in control group
Number of subjects: 142
Study 36409103 — intervention group
Group type: EXPERIMENTAL
Intervention: Various monetary lottery structures (total payout of $5 million)
Number of subjects: 863
Study 33440088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S vaccine (5×10^10 viral particles low dose or 1×10^11 viral particles high dose)
Number of subjects: 805
Study 33440088 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S vaccine
Number of subjects: 805
Study 36163093 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Number of subjects: 124879
Study 36163093 — intervention group
Group type: COMPARATOR
Intervention: BNT162b2
Number of subjects: 124879
Study 34000435 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine-pseudoephedrine (LP)
Number of subjects: 0
Study 34000435 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 0
Study 34000435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33053570 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 1.5 mg
Number of subjects: 10
Study 33053570 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone (MFP) 50 mg
Number of subjects: 10
Study 32304731 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefilled, nutritionally balanced online shopping cart (n = 27)
Number of subjects: 50
Study 32304731 — intervention group
Group type: COMPARATOR
Intervention: Nutrition education (n = 23)
Number of subjects: 50
Study 34245392 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT-6
Number of subjects: 410
Study 34245392 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 410
Study 34245392 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping Algorithm
Number of subjects: 410
Study 33931997 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Zusanli (ST36) and Zhongwan (CV12), 5‐15 Hz, 1‐5 mA, applied for 20 min, twice a day for 7 days.
Number of subjects: 68
Study 33931997 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard early enteral nutrition treatment through nasojejunal tube).
Number of subjects: 68
Study 35135549 — intervention group
Group type: EXPERIMENTAL
Intervention: PPT diet
Number of subjects: 23
Study 33721623 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoinositol 1000 mg twice daily
Number of subjects: 100
Study 33721623 — intervention group
Group type: COMPARATOR
Intervention: Control (no myoinositol)
Number of subjects: 100
Study 33721623 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoinositol group
Number of subjects: 100
Study 33721623 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 35197140 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral tube feeding
Number of subjects: 215
Study 35197140 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 215
Study 33939696 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% tranexamic acid (TXA) mouthwash
Number of subjects: 218